Helminths, Bedbugs, Scabies, and Lice Infections

Published on 10/02/2015 by admin

Filed under Emergency Medicine

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1572 times

177 Helminths, Bedbugs, Scabies, and Lice Infections

Nemathelminthes (Roundworms)

Nematodes range in length from 1 mm to up to 50 cm. Intestinal nematodes include Ascaris, Necator, and Ancylostoma, which develop in soil, whereas Strongyloides and Enterobius can be directly transmitted from person to person. With the exception of Strongyloides, most helminthes do not undergo replication within the host. Nematodes causing human disease include Dracunculus and filarial worms such as Wucheria, Brugia, and Onchocerca.

Intestinal Roundworms: Ascaris

Epidemiology

Ascariasis infects approximately 25% of the world’s population.1,2 It is prevalent in warm countries and areas of poor sanitation and is endemic to the southern United States. Ova can remain infective for several years. They are sensitive to temperatures higher than 65° C or lower than 20° C, direct sunlight, and organic solvents. Ascaris lumbricoides reaches up to 40 cm and is characterized by a constricted area at the junction of the first and middle thirds. The golden brown ovoid eggs measure 60 by 40 mcm.

Intestinal Roundworms: Necator and Ancylostoma (Hookworms)

Intestinal Roundworms: Strongyloides

Epidemiology

Strongyloides stercoralis is found in the tropics, subtropics, and in temperate areas, and it affects an estimated 55 million to 100 million persons.4 Strongyloides is endemic to Southeast Asia, Latin America, the West Indies, Bangladesh, Pakistan, Africa, Spain, and the Appalachian region of the United States. S. stercoralis is an unusual helminth in its ability to replicate within the human host, thus resulting in continuous autoinfection. The infection is often difficult to eradicate, especially in immunocompromised hosts (Box 177.1). The larvae can disseminate and can cause systematic disease and mortality.

Intestinal Roundworms: Enterobius (Pinworms)

Tissue Nematodes: Trichinella

Tissue Nematodes: Filaria

Epidemiology

Filarial nematodes are estimated to infect 170 million persons.1 Four main species cause most serious infections: Wucheria bancrofti, Brugia malayi, Onchocerca volvulus, and Loa loa. W. bancrofti is found in Africa, South America, Asia, the Pacific islands, and the Caribbean. Brugia species are found mainly in Southeast Asia, Asia, and Indonesia.

Tissue Nematodes: Onchocerca

Platyhelminthes (Flatworms)

The cestodes, or tapeworms, are segmented. Humans serve as intermediate hosts for Taenia solium, Echinococcus, Hymenolepis, Sparganosis, Coenurosis, and Dipylidiasis species. Taenia saginata and Diphyllobothrium also can infect humans, although these species cannot complete their life cycle within human hosts. Tapeworm eggs are transmitted by the fecal-oral route and are endemic in areas with poor sanitation and livestock.

Cestode: Taenia Solium (Pork Tapeworm)

Treatment

Calcified cysts do not warrant antiparasitic therapy.10 Patients with seizures may be treated with antiepileptics, and occasionally endoscopic surgery or ventriculoperitoneal shunting is necessary to relieve obstructive hydrocephalus. Corticosteroids may help mitigate cerebrovascular complications and may be used in the treatment of cysticercotic encephalitis.

Cestode: Echinococcus

Cestode: Diphyllobothrium (Fish Tapeworm)

Trematoda: Schistosoma

Epidemiology

Human schistosomiasis, also known as bilharziasis, remains a serious health threat in Africa, Southeast Asia, South America, and the Middle East.1 Schistosomiasis is a complex of acute and chronic parasitic infections caused by digenetic blood nematodes. Infections with Schistosoma haematobium (bladder fluke), Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, and Schistosoma intercalatum (intestinal flukes) cause illness in humans. Schistosomes have been documented to infect humans for thousands of years and are associated with agricultural civilizations of the great river valleys. Hematuria, most likely caused by S. haematobium, occurred in ancient Egypt and Mesopotamia.13

Signs and Symptoms

Patients may be asymptomatic initially, or they may show mild pruritic maculopapular skin lesions within hours to days after exposure to cercariae. Four to 8 weeks after invasion, some patients may present with fever, eosinophilia, lymphadenopathy, and hepatosplenomegaly. Acute schistosomiasis or Katayama fever resembles serum sickness, and it appears to be related to antigen excess during sexual maturation of the parasite. It is associated with a mortality rate of up to 25%.13

Chronic schistosomiasis persisting for months to years after primary exposure is more common. A granulomatous reaction to Schistosoma eggs, coupled with host cell–mediated inflammatory response lead to organomegaly and obstruction. Patients may present with abdominal pain, hematemesis, ascites, hematuria, dysuria, vulvar or perianal lesions, dyspnea on exertion, fatigue, cough, chest pain, or seizures, depending on the site of infection and the involvement of the body system.

Eggs induce an immune response as they travel to the liver, intestine, bladder, and rarely, to the brain or spinal cord. Granuloma formation in the bowel wall with S. mansoni or S. japonicum may cause bloody diarrhea, cramping, and colonic polyposis. Schistosoma can also cause pulmonary and CNS disease, with sequelae including pulmonary hypertension, cor pulmonale, epilepsy, and transverse myelitis.13

Egg retention and granuloma formation in the urinary tract with S. haematobium can lead to hematuria, urinary tract infections, glomerulonephritis, obstructive uropathy, dysuria, and bladder polyps and ulcerations. S. haematobium is considered a carcinogen in squamous cell bladder cancer.13

Treatment

Early treatment with cidal drugs may exacerbate Katayama fever, and concomitant steroid therapy is recommended. Patients with long-term infection may require procedures such as bladder stents, endoscopic treatment, or surgery.

Helminths cause a large burden of disease, yet their coevolution with humans and adaptation to our immune defenses may be beneficial (Box 177.2). Numerous epidemiologic and experimental studies have noted the low prevalence of allergy and autoimmune disease among populations with chronic helminth infections. Helminth infections generally cause a skewed type 1 helper T-cell (Th2) response. The Th1 arm of the immune system is often suppressed or downregulated. Populations with chronic helminthiases may not clear microbial infections adequately or respond optimally to vaccination.14,15 Schistosoma and Onchocerca infections appear to decrease tetanus and tuberculosis vaccine efficacy, and Ascaris infection similarly dampens the immune response to Mycoplasma pneumonia vaccination.16

Box 177.2 Helminth Immunomodulation

“The hygiene hypothesis suggests that microbes and worms are important for shaping and tuning the development and function of our immune system.”18

As developed countries experience better sanitation and reduced exposure to infectious disease agents, the immune system may be left “uneducated” and may develops “incorrect” or uncontrolled inflammation responses: rhinitis, atopic dermatitis, asthma, inflammatory bowel disease, multiple sclerosis, and type 1 diabetes mellitus.17 Helminth infections as therapies have been observed to decrease colitis in both murine and human models. A few studies have shown benefit from Trichuris infection in patients with inflammatory bowel disease; similar results have been reported in patients with multiple sclerosis.14,1618 Much more research is needed to characterize human-helminth immunomodulatory dynamics. Genetics and environment play important roles.

Bedbugs

Epidemiology

Bedbugs, or cimicids, are insects that have plagued humankind since ancient Egypt.19 These ectoparasites are found in temperate and tropical regions worldwide, and global infestations are increasing. Much media attention has been paid to bedbugs, and millions of dollars have been spent in the hospitality and private sectors. Travelers, backpackers, immigrants, guest workers, the homeless, and persons sharing close quarters, such as military barracks and dormitories, are potential hosts and vectors.

Scabies

Epidemiology

Scabies is a common parasitic infection caused by the mite Sarcoptes scabiei var. hominis, an arthropod of the order Acarina. Worldwide prevalence is estimated at 300 million.23 Scabies is endemic in sub-Saharan Africa, South and Central America, India, the South Pacific, and among Aboriginal communities in Australia. Additionally, infestations are sporadic in industrial countries. Overcrowding, poor hygiene and poor nutrition, poverty, war, and dementia are predisposing factors. Despite the stigma of scabies as an infection of the poor, scabies affects all ethnic and socioeconomic groups.

Transmission and Life Cycle

These obligate parasites complete their entire life cycle on humans. Scabies mites measure 0.2 to 0.5 mm in length, naked to the human eye. Only the female mite burrows into the skin, where the mite tunnels at a rate of 2 mm/day. The parasite can survive approximately 36 hours away from the human host. Each mite lays approximately 10 to 25 eggs and then dies in the stratum granulosum. Larvae hatch in 3 to 4 days, molt, then leave the burrow for the surface, copulate, and continue the cycle. Maturation is complete in 15 days.

The number of mites infesting a person usually ranges from 5 to 15, although thousands may be present in patients with crusted scabies. Symptoms of infestation usually manifest 3 to 6 weeks after the mite is acquired, but they may appear as soon as 1 day after the mite is acquired in cases of reinfestation, as a result of a hypersensitivity reaction. The primary mode of transmission is direct skin-to-skin contact. Investigators estimate that a 15- to 20-minute encounter is sufficient to transmit the mite. Transmission through shared clothing or other objects is rare, but it may occur with crusted scabies. Mites crawl at a rate of 2.5 cm/minute on human skin. The greater the parasite load, the greater is the chance of transmission. Sexual transmission also occurs. Immunocompromised hosts, including those who are HIV positive, HTLV-1 positive, undergoing immunosuppressant therapies, and malnourished, are at higher risk for developing crusted (Norwegian) scabies.

Signs and Symptoms

Intense, intractable, pruritic dermatitis with erythematous papulovesicular lesions characterize scabies infections. The itch is usually worse at night or after a hot shower. Skin burrows, gray serpiginous lines 1 to 10 mm in length, are pathognomonic findings. In adults, burrows and nodules are usually found in interdigital web spaces, axillary folds, extremities, buttocks, nipples, and genitals. Very young children and immunocompromised persons may have facial and neck lesions. Lesions to palms and soles, pinkish brown nodules, and acral pustules are unique to infested infants.

Crusted, or Norwegian, scabies is usually confined to immunocompromised, older, cognitively impaired, and institutionalized patients. Presumably, the lack of scratching may allow superinfection to occur.24 Crusted scabies represents a hyperinfection with thousands to millions of mites present. The lesions appear hyperkeratotic, similar to psoriatic papules, and can cover large areas of the scalp, face, neck, and extremities. Skin crusts may be loose or adherent, flaky or thick. Nail involvement is common with crusted scabies, as are eczematization and impetigo. Large flakes of epidermis slough off, carrying mites and furthering transmission. In crusted scabies, high levels of IgE and IgG and peripheral eosinophilia are present.24

Nodular scabies manifests with pruritic, violaceous nodules localized to the groin, axilla, and male genitalia. These nodules may represent a variant hypersensitivity reaction because mites are not found within them. Rarely, bullous lesions may occur with scabies, perhaps because of superinfection with Staphylococcus. Pyodermas, or bacterial skin infections, may be secondary to scabies infections, especially in the tropics.25

Head Lice

Treatment

Three main avenues exist for treatment: mechanical removal, topical agents, and oral therapy (Table 177.1). Children can return to school immediately after completion of the first application of a topical insecticide. Wet hair combing to remove P. humanus capitis nits and adults is not as effective as the use of topical agents. Infested clothing and bed linen should be washed in hot water, dry cleaned, or discarded.

Table 177.1 Treatment of Helminth Infections

ORGANISM TREATMENT PRECAUTIONS AND COMMENTS
Roundworms: Intestinal    
Ascaris Albendazole 400 mg PO × 1
Mebendazole 500 mg PO × 1
Mebendazole 100 mg PO bid × 3 days
Pyrantel pamoate 11 mg/kg × 1
Maximum dose, 1 g
  Ivermectin 150-200 mcg/kg PO × 1 Lactating/pregnant women
Weight > 15 kg
Necator, Ancylostoma Albendazole 400 mg PO × 1
Mebendazole 500 mg PO × 1 or 100 mg PO bid × 3 days
Pyrantel pamoate 11 mg/kg PO × 3 days
Supplemental iron PO
Maximum dose, 1 g
Strongyloides: simple Ivermectin 200 mcg/kg PO × 2 days; ± repeat in 1-2 wk Lactating/pregnant women
Weight > 15 kg
  Albendazole 400 mg PO bid × 3-7 days; ± repeat in 1-2 wk  
Strongyloides: disseminated Ivermectin 200 mcg/kg PO once daily; continue +2 wk after symptom resolution
+ Albendazole or thiabendazole
Lactating/pregnant women
Weight > 15 kg
  Albendazole 400 mg PO bid; continue +2 wk after symptom resolution
Thiabendazole 25 mg/kg PO bid; continue +2 wk after symptom resolution
 
Enterobius Albendazole 400 mg PO × 1
Mebendazole 100 mg PO × 1
Pyrantel pamoate 11 mg/kg PO × 1
Maximum dose, 1 g
TOC for pregnant women
Trichuris Albendazole 400 mg PO × 3 days
Mebendazole 200 mg PO × 3 days
Ivermectin 200 mcg/kg PO × 3 days
Lactating/pregnant women
Weight > 15 kg
Roundworms: Tissue    
Trichinella: mild Supportive therapy  
Trichinella: hypersensitivity Corticosteroid taper  
Trichinella: enteric only Albendazole 15 mg/kg/day PO × 10-15 days, may repeat in 5 days
Mebendazole 5 mg/kg/day PO × 10-15 days, may repeat in 5 days
Corticosteroids if severe disease
 
Cutaneous larva migrans Albendazole 400-800 mg/day PO × 3-5 days
Ivermectin 200 mcg/kg PO × 2 days
 
Lymphatic filariasis
 Wucheria bancrofti
 Brugia malayi
Diethylcarbamazine 6 mg/kg/day PO × 12 days
Albendazole 400 mg PO bid × 21-30 days
Doxycycline 200 mg PO once daily × 8 wk
Hypersensitivity reaction
  Albendazole 400 mg PO × 1 + diethylcarbamazine 6 mg/kg PO × 1 or
Ivermectin 200-400 mcg/kg PO × 1
Microfilariacidal only
Lactating/pregnant women
Weight > 15 kg
Loa loa Diethylcarbamazine 8-10 mg/kg/day PO × 21 days
Diethylcarbamazine 300 mg/week for prophylaxsis
Microfilariacidal only
Mansonella ozzardi Ivermectin 200 mcg/kg PO × 1 Lactating/pregnant women
Weight > 15 kg
Mansonella perstans Mebendazole 100 mg PO bid × 30 days
Albendazole 400 mg PO bid × 10 days
Often not effective
Mansonella streptocerca Diethylcarbamazine 6 mg/kg/day PO × 14-21 days
Ivermectin 150 mcg/kg PO × 1
Lactating/pregnant women
Weight > 15 kg
Onchocerca Ivermectin 150-200 mcg/kg PO × 1; can repeat in 3-6 mo Microfilariacidal only
Mazzotti reaction
  Doxycycline 100-200 mg PO once daily × 6 wk
Mebendazole 1 g PO bid × 28 days
Pulmonary eosinophilia
Flatworms: Cestoidea    
Taenia solium: intestinal Praziquantel 10-20 mg/kg PO × 1
+ Cimetidine
Hepatic impairment, does not inactivate eggs released from dead adult worms
  Niclosamide 2 g PO  
Taenia solium: neurocysticercosis Praziquantel 50-60 mg/kg/day PO × 15-30 days + steroids
albendazole 15 mg/kg/day PO × 8-30 days
If > 60 kg, then 400 mg PO bid × 8-30 days
+ Anticonvulsants and corticosteroids:
Dexamethasone 16-24 mg/day PO
Followed by prednisone 1 mg/kg/day PO
Taper over 2-3 wk
± Endoscopic surgery/ventriculoperitoneal shunt
Hepatic impairment
Maximum, 800 mg/day
Echinococcus Nonsurgical cysts: albendazole 10-15 mg/kg/day or mebendazole 40-50 mg/kg/day for 3-6 months
Surgical adjuncts: albendazole 15 mg/kg/day PO, start minimum of 4 days before procedure and continue for 8 weeks after procedure
Intraoperative: praziquantel 40 mg/kg/day PO
PAIR 90% ethanol or 20% hypertonic saline
Neutropenia and liver toxicity with prolonged albendazole and mebendazole use
  Praziquantel 50 mg/kg/day PO × 2 wk Hepatic impairment
Diphyllobothrium latum Praziquantel 25 mg/kg PO × 1  
Diphyllobothrium other spp. Praziquantel 10 mg/kg PO × 1
Niclosamide 2 g PO × 1 adults
1 g PO × 1 pediatrics >6 yr old
 
Flukes: Trematoda    
Schistosoma Praziquantel 40-60 mg/kg/day PO × 1 day Age > 4 yr
Hepatic impairment
Other Flukes    
Clonorchis
Fasciola
Opisthorchis
Paragonimus
Praziquantel 75 mg/kg/day PO × 1-2 days
Albendzole 10 mg/kg/day PO × 7 days
Hepatic impairment
Bedbugs: Cimex spp. Antipuritics ± corticosteroids  
Scabies: Sarcoptes spp. Permethrin 5% topical, 8-14 hr; wash off ± repeat 1 wk Age > 2 mo
First-line treatment in United States
Resistance reported
  Lindane 1% topical, 6 hr then wash; can repeat in 1 wk Lactating/pregnant women
Increased seizure risk
Aplastic anemia risk
Weight > 50 kg
Age > 6 mo
Resistance reported
  Crotamiton 10% topical bid × 5 days
or × 1 for 48 hr total
Lactating/pregnant women
  Benzyl benzoate 10-25% 2-3 × in 1 day Lactating/pregnant women
Age > 2 yr
Not available in United States
Effective in permethrin-resistant scabies
  Sulfur 2-10% petroleum, 2-3 days Dermatitis
Stains clothing
Not available in United States
  Sulfur 10% may be more effective than permethrin for crusted scabies23  
  Malathion 0.5% 8-12 hr Lactating/pregnant women
Age > 6 mo
Not available in United States
  Ivermectin 0.8% topical Lactating/pregnant women
Weight > 15 kg
  Ivermectin 200 mcg/kg PO × 1; repeat in 2 wk
or Ivermectin 250-350 mcg/kg PO × 1
 
Lice: Pediculus humanus capitis Permethrin 1% topical 8-14 hr; wash off ± repeat 1 wk
May use 5% topical if >2 mo old
Resistance reported
  Lindane 1% topical, 6 hr then wash; can repeat in 1 wk Lactating/pregnant women
Increased seizure risk
Aplastic anemia risk
Weight > 50 kg
Age > 6 mo
Resistance reported
  Malathion 0.5% topical 12 hr Age > 6 mo
Flammable
Ovicidal
Resistance reported29
  Carbaryl 0.5% topical Carcinogenic26
Available in United Kingdom
  Benzyl alcohol 5%, topical 10 min; repeat in 10 days Age > 6 mo
Approved in United States30,31
  Ivermectin 200-400 mcg/kg PO × 1; repeat in 7-10 days Lactating/pregnant women
Weight > 15 kg
  Ivermectin 200 mcg/kg PO days 1, 2, 10 Good option in resource-poor area36,37
  Spinosad 0.9% cream 10 min; wash Under development32
  Dimethicone 4% lotion Used in United Kingdom, Europe, Brazil33,34
  Essential oils: lavender, coconut, citronella, anise, ylang-ylang No investigative trials35
  Occlusive dressings: petroleum jellyMayonnaise, olive oil Anecdotal home remedies
  LouseBuster 30 min Expensive
Special training required
No case-control trials27

bid, Twice daily; PAIR, percutaneous aspiration, infusion of scolicidal agents, and reaspiration; PO, orally; tid, three times daily.

References

1 Hotez PF, Brindley PJ, Bethony JM, et al. Helminth infections: the great neglected tropical diseases. J Clin Invest. 2008;118:1311–1321.

2 Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections. JAMA. 2008;299:1937–1948.

3 Loukas A, Constant SL, Bethony JM. Immunobiology of hookworm infection. FEMS Immunol Med Microbiol. 2005;42:115–124.

4 Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother. 2007;41:1992–2001.

5 Boulware DR, Stauffer WM, Hendel-Paterson BR, et al. Maltreatment of Strongyloides infection: case series and worldwide physicians-in-training survey. Am J Med. 2007;120:545–551.

6 Allen JE, Adjei O, Bain O, et al. Of mice, cattle, and humans: the immunology and treatment of river blindness. PLoS Negl Trop Dis. 2008;2:217–225.

7 Mahanty S, Garcia H. Cysticercosis and neurocysticercosis as pathogens affecting the nervous system. Prog Neurobiol. 2010;91:172–184.

8 Jia WZ, Yan HB, Guo AJ, et al. Complete mitochondrial genomes of Taenia multiceps, T. hydatigena and T. pisiformis: additional molecular markers for a tapeworm genus of human and animal health significance. BMC Genomics. 2010;11:447–460.

9 Chow F, Garcia HH. Helminthic diseases: taeniasis and cysticercosis. In: Quah S, Heggenhougen K. International encyclopedia of public health. New York: Academic Press; 2008:361–368.

10 Garcia H, Del Brutto OH, Nash TE, et al. New concepts in the diagnosis and management of neurocysticercosis (Taenia solium). Am J Trop Med Hyg. 2005;72:3–9.

11 Zhang W, Roos AG, McManus DP. Mechanisms of immunity in hydatid disease: implications for vaccine development. J Immunol. 2008;181:6679–6685.

12 Scholz T, Garcia HH, Kuchta R, Wicht B. Update on the human broad tapeworm (genus Diphyllobothrium), including clinical relevance. Clin Microbiol Rev. 2009;22:146–160.

13 Mahmoud AAF. Schistosomiasis and other trematode infections. Fauci AS, Braunwald E, Kasper DL, et al. Harrison’s principles of internal medicine, 17th ed, New York: McGraw-Hill, 2008.

14 Klaus JE. Can helminths of helminth-derived products be used in humans to prevent or treat diseases? Trends Immunol. 2009;30:75–82.

15 Jackson JA, Friberg IM, Little S, Bradley JE. Review series on helminths, immune modulation and the hygiene hypothesis: immunity against helminths and immunological phenomena in modern human populations: coevolutionary legacies? Immunology. 2008;126:18–27.

16 Moreau E, Chauvin A. Immunity against helminths: interactions with the host and the intercurrent infections. J Biomed Biotechnol. 2010;2010:428593.

17 Smits HH, Everts B, Hartgers FC, Yazdanbakhsh M. Chronic helminth infections protect against allergic diseases by active regulatory process. Curr Allergy Asthma Rep. 2010;10:3–12.

18 Wang LJ, Cao Y, Shi HN. Helminth infections and intestinal inflammation. World J Gastroenterol. 2008;14:5125–5132.

19 Reinhardt K, Siva-Jothy M. Biology of the bed bugs (Cimicidae). Annu Rev Entomol. 2007;52:351–374.

20 Benoit J, Del Grosso NA, Yoder JA, Denlinger DL. Resistance to dehydration between bouts of blood feeding in the bed bug, Cimex lectularius, is enhanced by water conservation, aggregation, and quiescence. Am J Trop Med Hyg. 2007;76:987–993.

21 Goddard J, DeShazo R. Bed bugs (Cimex lectularius) and clinical consequences of their bites. JAMA. 2009;301:1358–1366.

22 Romero A, Potter MF, Potter DA, Haynes KF. Insecticide resistance in the bed bug: a factor in the pest’s sudden resurgence? J Med Entomol. 2007;44:175–178.

23 Hicks M, Elston DM. Scabies. Dermatol Ther. 2009;22:279–292.

24 Walton SF. The immunology of susceptibility and resistance to scabies. Parasite Immunol. 2010;32:532–540.

25 Hay RJ. Scabies and pyodermas: diagnosis and treatment. Dermatol Ther. 2009;22:466–474.

26 Nutanson I, Steen CJ, Schwartz RA, Janniger CK. Pediculus humanus capitis: an update. Acta Dermatoveneron Alp Panonica Adriat. 2008;17:147–154. 156-157, 159

27 Frankowski BL, Bocchini JA, Jr. Committee on School Health the Committee on Infectious Diseases. Head lice. Pediatrics. 2010;126:392–403.

28 Chosidow O, Giraudeau B, Cottrell J, et al. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010;362:896–905.

29 Heymann WR. Head lice treatments: searching for the path of least resistance. J Am Acad Dermatol. 2009;61:323–324.

30 Hussar DA. New drugs: tapentadol hydrochloride, tolvaptan, and benzyl alcohol. J Am Pharm Assoc. 2009;49:704–708. (2003)

31 Meinking TL, Villar ME, Vicaria M, et al. The clinical trials supporting benzyl alcohol lotion 5% (Ulesfia): a safe and effective topical treatment for head lice (pediculosis humanus capitis). Pediatr Dermatol. 2010;27:19–24.

32 Stough D, Shellabarger D, Quiring J, Gabrielsen AA, Jr. Efficacy and safety of spinosad and permethrin creme rinses for pediculosis capitis (head lice). Pediatrics. 2009;124:389–395.

33 Kurt O, Balcioglu IC, Burgess IF, et al. Treatment of head lice with dimethicone 4% lotion: comparison of two formulations in a randomized controlled trial in rural Turkey. BMC Public Health. 2009;9:441–450.

34 Heukelbach J, Pilger D, Oliveira FA, et al. A highly efficacious pediculicide based on dimethicone: randomized observer blinded comparative trial. BMC Infect Dis. 2008;8:115–125.

35 Burgess IF. Current treatments for pediculosis capitis. Curr Opin Infect Dis. 2009;22:131–136.

36 Munirathinam A, Sunish IP, Rajendran R, Tyagi BK. Impact of ivermectin drug combinations on Pediculus humanus capitis infestation in primary schoolchildren of south Indian rural villages. Int J Dermatol. 2009;48:1201–1205.

37 Pilger D, Heukelbach J, Khakban A, et al. Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial. Bull World Health Organ. 2010;88:90–96.